http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0772444-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2227a4ee4bf2e2b230299ca24fd3308a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- |
| filingDate | 1995-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71afe8ed8d950bc4cfa1642805a6aca1 |
| publicationDate | 1997-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0772444-A1 |
| titleOfInvention | Use of the enantiomers of oxazophosphorines, e.g. ifosfamide, in anti-tumour therapy, for reducing side-effects |
| abstract | A product containing respective enantiomers of an oxazophosphorine, each substantially free of the other, as a combined preparation for separate, simultaneous or sequential use in anti-tumour therapy. The active component may be ifosfamide. Levoifosfamide is preferred for single drug therapy, owing to its more rapid metabolism. |
| priorityDate | 1994-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.